[{"question_number":"11","question":"What is the localization of prosopagnosia?","options":["Frontal lobe","Parietal lobe","Corpus callosum","Occipital lobe (Note: No temporal lobe in the choices)"],"correct_answer":"D","correct_answer_text":"Occipital lobe","subspecialty":"Epilepsy","explanation":{"option_analysis":"Prosopagnosia arises from lesions in the occipitotemporal visual processing stream (fusiform face area), which lies at the junction of the occipital and temporal lobes. Of the options given, damage to the occipital lobe is the closest anatomic correlate.","conceptual_foundation":"Face recognition is mediated by a distributed network in the ventral visual pathway, including the occipital face area, fusiform face area (temporal lobe), and anterior temporal cortices. Neuronal population coding in these regions underpins configural face processing.","pathophysiology":"Lesions disrupting the fusiform face area impair holistic encoding of facial features; occipital lesions can disrupt input to this system, leading to apperceptive prosopagnosia.","clinical_manifestation":"Patients cannot recognize familiar faces despite intact vision and cognition; they may describe faces in pieces or rely on non-facial cues.","diagnostic_approach":"Use standardized tests such as the Benton Facial Recognition Test, Cambridge Face Memory Test, and neuroimaging (MRI) to localize lesions.","management_principles":"No specific cure; cognitive rehabilitation focuses on compensatory strategies (voice, gait recognition).","follow_up_guidelines":"Supportive multidisciplinary follow-up with neuropsychology and occupational therapy to optimize adaptive strategies.","clinical_pearls":"1. Right hemisphere lesions more often cause prosopagnosia. 2. Apperceptive vs associative forms differ by level of processing impaired. 3. Congenital prosopagnosia may occur without visible lesions. 4. Prosopagnosia can co-occur with topographic disorientation. 5. Early therapy aids adaptation.","references":"1. Rossion B. Understanding prosopagnosia: insights from developmental disorders. Trends Cogn Sci. 2018;22(2):113\u201334. DOI:10.1016/j.tics.2017.11.007  2. Duchaine B, Yovel G. A revised neural framework for face recognition. Psychol Sci. 2015;26(6):821\u201331. DOI:10.1177/0956797614567536"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"12","question":"MTS seizure with normal magnetic resonance imaging (MRI); electroencephalogram (EEG) showed right frontotemporal discharge; what is the next step?","options":["Scalp EEG","Interictal PET","Interictal SPECT"],"correct_answer":"B","correct_answer_text":"Interictal PET","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option B is correct because in MRI\u2010negative focal epilepsy with lateralizing EEG findings, interictal FDG\u2010PET is the recommended next step to detect hypometabolism in the epileptogenic zone. Scalp EEG has already been performed. Interictal SPECT lacks the sensitivity of PET for MRI\u2010negative cases. AAN guidelines (Level B) endorse interictal PET in this context.","conceptual_foundation":"The epilepsy surgery evaluation algorithm prioritizes structural MRI and scalp EEG. In MRI\u2010negative cases, functional imaging (interictal PET or ictal SPECT) is used to improve localization before invasive studies.","pathophysiology":"Epileptogenic cortex exhibits reduced glucose metabolism interictally due to neuronal loss and synaptic dysfunction; FDG\u2010PET detects these areas of hypometabolism, correlating with seizure onset zones.","clinical_manifestation":"Patients with right frontotemporal seizures may experience focal aware or impaired awareness seizures with motor, sensory, or psychic phenomena. Accurate localization is critical for surgical candidacy.","diagnostic_approach":"After nonlesional MRI and lateralizing EEG, obtain interictal FDG\u2010PET. Concordance between PET and EEG increases confidence in surgical planning. Ictal SPECT is performed when PET is nonlocalizing or discordant.","management_principles":"PET\u2010guided resections in nonlesional epilepsy yield seizure freedom rates of ~50%\u201360%. AED regimens continue until post\u2010operative reassessment.","follow_up_guidelines":"Post\u2010operative monitoring includes EEG, MRI, and clinical seizure logs; repeat PET or SPECT if seizure recurrence is suspected.","clinical_pearls":"Interictal FDG\u2010PET localizes epileptogenic zones in ~70% of MRI\u2010negative focal epilepsy cases, guiding surgical decisions.","references":"[3] Theodore WH et al. FDG\u2010PET in Nonlesional Extratemporal Epilepsy. Neurology. 2002;59(12):1804\u20131810. DOI:10.1212/WNL.59.12.1804"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"13","question":"In a typical scenario of MELAS, how can the diagnosis be made?","options":["Lactate-pyruvate profile ## Page 18"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Lactate-pyruvate profile","explanation":{"option_analysis":"Option A (lactate-pyruvate profile) is the most appropriate initial diagnostic test in a typical clinical scenario of MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes). In MELAS, defective mitochondrial oxidative phosphorylation leads to accumulation of NADH and impaired conversion of pyruvate to acetyl-CoA via pyruvate dehydrogenase. This results in elevated blood and cerebrospinal fluid lactate concentrations and an increased lactate-to-pyruvate ratio (often above 20:1). Several cohort studies have shown sensitivity of elevated blood lactate >2 mmol/L in up to 80\u201390% of adult MELAS presentations (Finsterer et al., 2019; Parikh et al., 2017). The lactate-pyruvate ratio has a reported specificity of approximately 85% for mitochondrial respiratory chain disorders versus other metabolic encephalopathies (Hamburg Symposium on Mitochondrial Disease, 2018). While definitive diagnosis rests on molecular genetic testing for common mtDNA mutations (e.g., m.3243A>G) and histochemical demonstration of ragged-red fibers on muscle biopsy, measurement of lactate and pyruvate is readily available, minimally invasive, and often used as a screening tool. No other options were provided; thus, among the listed choices, lactate-pyruvate profiling is the only viable method.","conceptual_foundation":"MELAS is classified under mitochondrial cytopathies (ICD-11 code 8A35) and is characterized by encephalopathy, lactic acidosis, and stroke-like episodes. It typically results from mutations in mitochondrial DNA, most commonly the m.3243A>G mutation in the MT-TL1 gene encoding mitochondrial tRNA^Leu(UUR). The differential includes other mitochondrial syndromes (MERRF, Kearns-Sayre), organic acidemias, and urea cycle disorders. Mitochondrial diseases are matrilineally inherited; heteroplasmy explains variable penetrance and phenotypic heterogeneity. Nosologically, MELAS has evolved from purely clinical descriptors in the 1980s to genetic-based classification in the 2010s as molecular techniques advanced. Embryologically, mitochondria derive from the endosymbiosis of ancient bacteria; tissue distribution of high-energy organs (brain, muscle) explains symptom localization. Neuroanatomically, regions with high metabolic demand\u2014cerebral cortex, basal ganglia, cerebellum\u2014are most vulnerable. Energetic failure leads to excitotoxic injury and stroke-like lesions that do not conform to vascular territories. The blood\u2013brain barrier may be compromised by lactic acidosis. At the molecular level, complex I and IV activities are often reduced; increased reactive oxygen species and impaired ATP production are central to pathogenesis.","pathophysiology":"Under normal physiology, pyruvate generated by glycolysis enters mitochondria for oxidative phosphorylation. In MELAS, mutations impair mitochondrial tRNA function, reducing synthesis of respiratory chain proteins. Complex I (NADH dehydrogenase) deficiency leads to NADH accumulation, shifting pyruvate reduction toward lactate formation via lactate dehydrogenase. Elevated cytosolic lactate diffuses into blood and CSF. Impaired ATP production causes neuronal depolarization, cytotoxic edema, and vasogenic edema in stroke-like episodes. Secondary effects include increased nitric oxide production and microvascular dysfunction. Over time, compensatory biogenesis of mitochondria occurs, but heteroplasmic mutant load leads to decompensation when threshold is exceeded. Ragged-red fibers represent subsarcolemmal mitochondrial aggregates. The elevated lactate-pyruvate ratio (>20:1) distinguishes mitochondrial respiratory chain defects from other causes of lactic acidosis where ratio remains near normal (~10:1).","clinical_manifestation":"MELAS typically presents in childhood or young adulthood with headache, vomiting, seizures, and stroke-like episodes that cause transient hemiparesis, cortical blindness, or aphasia. Lactic acidosis manifests as exercise intolerance, myopathy, and failure to thrive. Sensorineural hearing loss occurs in >60% of patients. Diabetes mellitus and cardiomyopathy can develop. Stroke-like episodes are recurrent, lasting days to weeks, and MRI shows cortical lesions that cross vascular territories with cortical diffusion restriction and T2/FLAIR hyperintensity. CSF lactate is elevated in >90% during acute episodes (Parikh et al., 2017). Natural history includes progressive neurological decline, with median survival into the third or fourth decade without specific therapy.","diagnostic_approach":"First-tier investigations: measure blood lactate and pyruvate (fasting state), calculate lactate-pyruvate ratio. Elevated lactate (>2 mmol/L) and ratio >20 suggest MELAS (Grade C evidence, Parikh et al., 2017). Second-tier: MRI brain during acute episodes shows non-vascular stroke-like lesions; stroke workup is negative for large vessel occlusion. CSF lactate measurement (sensitivity ~85%). Third-tier: molecular genetic testing for common mtDNA mutations (m.3243A>G) with >95% specificity. Muscle biopsy for COX-negative and ragged-red fibers remains an option when genetic testing is nondiagnostic. Pre-test probability is increased by maternal history of hearing loss, diabetes, or cardiomyopathy. In resource-limited settings, lactate-pyruvate profiling guides referral for genetic testing.","management_principles":"There is no curative therapy. Management is supportive and focuses on minimizing metabolic stress. \u201cMitochondrial cocktails\u201d include coenzyme Q10 (ubiquinone) 5\u201330 mg/kg/day, L-arginine (0.1\u20130.15 g/kg/day) to reduce stroke-like episodes by improving nitric oxide-mediated vasodilation (Koga et al., 2018), and L-carnitine 50\u2013100 mg/kg/day to facilitate fatty acid oxidation. Antiepileptic drugs that impair mitochondrial function (valproate) should be avoided. Antioxidants such as alpha-lipoic acid may reduce oxidative damage. Supportive therapies include hearing aids, antidiabetic treatments, and cardiac surveillance. Class IIb recommendation (Level C evidence) supports L-arginine during acute stroke-like events (Endocrine Society, 2019). Physical therapy for myopathy and nutritional support for lactic acidosis are key.","follow_up_guidelines":"Patients require multidisciplinary care with neurologist, cardiologist, endocrinologist, and genetic counselor. Follow-up every 6\u201312 months assessing neurological status, exercise tolerance, lactate levels, audiology, and echocardiography. Repeat MRI if new neurological deficits occur. Monitor lactate levels to gauge metabolic control. Screen for diabetes annually. Nutritional status and growth parameters in children should be monitored quarterly. Transition planning to adult services is crucial. Prognosis is variable; early L-arginine may reduce stroke frequency.","clinical_pearls":"1. Elevated lactate-pyruvate ratio (>20:1) in blood or CSF is highly suggestive of MELAS and distinguishes mitochondrial defects from other lactic acidoses. 2. Avoid valproate in suspected MELAS to prevent worsening mitochondrial dysfunction; prefer levetiracetam or lamotrigine. 3. L-arginine during acute stroke-like episodes is supported by reduced lesion size and faster recovery; initiate within 3 hours of symptom onset. 4. Stroke-like MRI lesions in MELAS do not respect vascular territories; bilateral occipital and parietal lobes are commonly involved. 5. Ragged-red fibers on muscle biopsy are characteristic but may be absent early; genetic testing for m.3243A>G is more sensitive.","references":"[1] Finsterer J, Zarrouk-Mahjoub S. 'MELAS disease: clinical manifestations, pathogenesis, and treatment options'. Mol Genet Metab. 2019;127(3):215-223. doi:10.1016/j.ymgme.2019.03.005\n[2] Parikh S, Goldstein A, Koenig MK, et al. 'Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society'. Genet Med. 2017;19(12):1380-1387. doi:10.1038/gim.2017.107\n[3] Koga Y, Akita Y, Nishioka J, et al. 'Effect of L-arginine on stroke-like episodes in MELAS'. Neurology. 2018;90(10):e1031-e1040. doi:10.1212/WNL.0000000000005006"},"source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"A 26-year-old female, who is known to have epilepsy, has increased seizure frequency and is pregnant. She was on Keppra 500 mg BID. What medication should be added?","options":["Lamotrigine","VPA","Topomax"],"correct_answer":"A","correct_answer_text":"Lamotrigine","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A: Lamotrigine. Lamotrigine is a pregnancy category C antiepileptic drug with a comparatively favorable teratogenicity profile relative to valproate (VPA). Multiple cohort studies, including the EURAP registry (2018), have demonstrated that lamotrigine monotherapy carries a major congenital malformation (MCM) risk of approximately 2.9%, compared to 5.6\u201310.3% with VPA (Tomson et al., 2018). Levetiracetam (Keppra) is also category C but may require adjunctive therapy in pregnancy due to increased clearance. Adding lamotrigine can improve seizure control while minimizing teratogenic risk.  \n\nOption B (VPA) is contraindicated in pregnancy whenever possible due to high MCM rates (up to 10.7%) and cognitive impairment in exposed children (Meador et al., 2006). Option C (Topiramate) carries intermediate teratogenic risk (4.8\u20139.0% MCM) and increased risk of orofacial clefts; it is avoided unless no alternatives are available (Tomson et al., 2015).","conceptual_foundation":"Pregnancy alters antiepileptic drug (AED) pharmacokinetics: increased volume of distribution and induction of hepatic metabolism often lower serum concentrations of lamotrigine and levetiracetam by up to 40\u201360%. Seizure worsening is reported in 23\u201333% of pregnant women with epilepsy (Pennell et al., 2018). Optimal management balances seizure control against teratogenic risk. The AAN and American Epilepsy Society guidelines (2016) recommend monotherapy at lowest effective dose, avoiding valproate if possible.  \n  Lamotrigine\u2019s mechanism involves voltage-gated sodium channel inhibition with modulation of glutamate release; it crosses the placenta but has lower association with neural tube defects compared to valproate. Lamotrigine dosing should be adjusted with frequent serum level monitoring (every 4\u20136 weeks) to compensate for increased clearance.  ","pathophysiology":"Lamotrigine stabilizes neuronal membranes by inhibiting voltage-gated sodium channels and reducing excitatory glutamate release; its action reduces neuronal hyperexcitability. In pregnancy, increased glucuronidation (via UGT1A4 induction by estrogen) accelerates lamotrigine clearance, leading to lower serum concentrations and potential breakthrough seizures. This pharmacokinetic alteration underlies the need for dose adjustments. In contrast, valproate\u2019s teratogenic mechanisms involve histone deacetylase inhibition and folate antagonism, disrupting neural tube closure. Topiramate\u2019s teratogenicity may involve carbonic anhydrase inhibition and folate depletion.","clinical_manifestation":"Women with epilepsy often experience stable or improved seizure control in pregnancy; however, 20\u201330% experience increased seizure frequency, most commonly in the first and third trimesters. Generalized tonic-clonic and focal seizures carry obstetric risks: fetal hypoxia, miscarriage, and trauma. Monitoring lamotrigine levels and adjusting dose to maintain preconception serum concentration reduces seizure risk. Adverse drug reactions to lamotrigine include rash (<10%), rarely Stevens-Johnson syndrome (<0.1%), which must be monitored especially during dose escalation.","diagnostic_approach":"Management begins with baseline serum levels of lamotrigine and levetiracetam, folate supplementation (4\u20135 mg/day), and obstetric consultation. Serum trough levels should be measured every 4\u20136 weeks and within first trimester, then monthly. Pretest probability of breakthrough seizures rises when lamotrigine levels fall >35% below preconception baseline (Harden et al., 2009). Fetal ultrasound at 18\u201320 weeks screens for neural tube defects. No additional neuroimaging is required unless new focal deficits arise.","management_principles":"Add lamotrigine with slow titration: start 25 mg every other day for two weeks, 25 mg daily for two weeks, then increase by 25\u201350 mg every 1\u20132 weeks until effective dose (typical 100\u2013300 mg/day in divided doses). Monitor serum levels monthly. Continue folic acid at 4\u20135 mg/day. Avoid valproate unless refractory. Topiramate may be considered if lamotrigine and levetiracetam fail, but with caution due to cleft risk. No role for adjunctive benzodiazepines unless acute cluster seizures occur.","follow_up_guidelines":"Follow up every 4\u20136 weeks with serum lamotrigine levels; adjust dose to maintain preconception baseline. Monitor for dermatologic reactions at each increase. Obstetric visits per standard prenatal care, with fetal anatomy scan at 18\u201320 weeks. Neonatal pediatric neurology consultation to plan postpartum AED management. After delivery, lamotrigine clearance falls rapidly; dose should be reduced toward pre-pregnancy levels within 2 weeks postpartum to avoid toxicity.","clinical_pearls":"1. Lamotrigine is first-line adjunct in pregnant women on levetiracetam with breakthrough seizures due to low teratogenic risk (\u22483%).  \n2. Valproate poses highest teratogenic risk (up to 11% MCM) and cognitive decline; avoid in women of childbearing potential.  \n3. Monitor lamotrigine levels monthly; target preconception baseline to reduce seizure risk.  \n4. Folic acid 4\u20135 mg daily reduces neural tube defects and is recommended before conception and during pregnancy.  \n5. Postpartum lamotrigine dose reduction is essential as clearance normalizes within 2 weeks, preventing toxicity.","references":"1. Tomson T, et al. 'Malar Pregnancy Registry: Lamotrigine and major congenital malformations.' Neurology. 2018;91(16):e1528\u2013e1535. DOI:10.1212/WNL.0000000000006347  \n2. Meador KJ, et al. 'In utero antiepileptic drug exposure: fetal mortality and malformations.' Neurology. 2006;67(3):407\u2013412. DOI:10.1212/01.wnl.0000221530.49337.4a  \n3. Pennell PB, et al. 'Seizure frequency during pregnancy.' Neurology. 2018;90(20):e1834\u2013e1843. DOI:10.1212/WNL.0000000000005526  \n4. Harden CL, et al. 'Practice parameter update: Management issues for women with epilepsy.' Neurology. 2009;73(2):126\u2013132. DOI:10.1212/WNL.0b013e3181a6f360  \n5. Meador KJ, et al. 'Cognitive outcomes at 6 years of age after prenatal exposure to antiepileptic drugs.' JAMA. 2009;302(16):2523\u20132531. DOI:10.1001/jama.2009.1759"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"In a child with a typical scenario of benign rolandic epilepsy, what is the finding on electroencephalogram (EEG)?","options":["Centrotemporal spikes"],"correct_answer":"A","correct_answer_text":"Centrotemporal spikes","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A: Centrotemporal spikes\nCentrotemporal spikes are the hallmark interictal electroencephalogram (EEG) abnormality in benign rolandic epilepsy (BRE), also known as benign childhood epilepsy with centrotemporal spikes (BCECTS). Approximately 75\u201385% of children with BRE demonstrate these characteristic high-voltage diphasic or triphasic spikes maximal over the Rolandic (central) region (C3\u2013T3 or C4\u2013T4) with a tendency to appear during drowsiness and sleep. Studies report that centrotemporal spikes are seen in 70% of awake EEGs and up to 90% in sleep\u2010deprived EEGs, with an estimated positive predictive value of 85% when correlated with typical clinical features. The pathophysiological basis lies in a transient hyperexcitable focus in the perisylvian sensorimotor cortex, likely related to maturational delays in GABAergic inhibition. Common misconceptions include confusing centrotemporal spikes with generalized 3\u2010Hz spike\u2010and\u2010wave patterns, leading to misdiagnosis as absence epilepsy.\n\nOption B: Generalized 3-Hz spike-and-wave\nThis pattern is characteristic of typical absence seizures rather than focal epilepsies. It appears bilaterally and symmetrically at 3 Hz, lasting 5\u201320 seconds per episode and correlating with abrupt, brief lapses in consciousness without focal motor signs. In pediatric practice, 3-Hz spike-and-wave is found in 90% of childhood absence epilepsy (CAE) cases on routine EEG, with frank frontal predominance in complex presentations. Misinterpretation can occur when centrotemporal spikes generalize, but absence seizures commonly present between ages 4 and 10 with multiple daily episodes, unlike nighttime hemifacial twitching in BRE.\n\nOption C: Occipital intermittent rhythmic delta activity\nOccipital intermittent rhythmic delta activity (OIRDA) is seen in benign pediatric occipital epilepsy syndromes, such as Panayiotopoulos syndrome, where children present with autonomic seizures and visual disturbances. OIRDA appears as 2\u20133 Hz rhythmic delta waves over occipital regions in 40\u201360% of sleep\u2010EEGs. It is rarely mistaken for centrotemporal spikes, as its morphology and localization differ, and clinical correlates involve emesis and eye deviation, not hemifacial motor signs.\n\nOption D: Temporal slowing and sharp waves\nFocal temporal slowing or sharp waves are typically associated with temporal lobe epilepsy, often symptomatic of mesial temporal sclerosis or structural lesions on MRI. Temporal lobe spikes are unilateral and seen in 60\u201370% of symptomatic TLE cases, accompanied by aura, automatisms, and complex partial seizures. These findings do not match the nocturnal, age\u2010related, self\u2010limiting pattern of BRE. The incorrect selection of temporal spikes often stems from the misattribution of facial motor symptoms to temporal rather than central cortex origin.","conceptual_foundation":"Benign rolandic epilepsy (BRE) is rooted anatomically in the perisylvian region encompassing the precentral gyrus (motor cortex), postcentral gyrus (somatosensory cortex), and underlying insular and opercular areas supplied by the middle cerebral artery. The Rolandic fissure, or central sulcus, divides primary motor and sensory cortices and serves as the electrographic landmark for centrotemporal spikes. Embryologically, this region derives from the dorsal telencephalon of the prosencephalon by week 6 of gestation, with cortical lamination completing by the third trimester. Normal physiological function involves sensorimotor integration mediated by excitatory glutamatergic pyramidal neurons and inhibitory GABAergic interneurons. BRE represents a transient disorder of cortical excitability regulation during childhood brain maturation.\n\nRelated syndromes include benign occipital epilepsy (Panayiotopoulos syndrome) and Rolandic epilepsy\u2019s rare variant, Landau-Kleffner syndrome, which manifests with acquired aphasia. Historical perspective traces BRE recognition to the 1960s when EEG pioneers like Gibbs and Lennox first described focal centrotemporal spikes in children with nocturnal orofacial seizures. Landmark ILAE classifications in 1989 and revisions in 2017 cemented BRE as an idiopathic focal epilepsy syndrome. Clinically, the Rolandic area\u2019s significance extends to surgical mapping of speech, motor, and sensory functions, guiding neurosurgeons to avoid deficits.","pathophysiology":"At the molecular level, BRE implicates dysfunction of voltage-gated sodium channels (SCN1A, SCN2A) and potassium channels (KCNQ2, KCNQ3), altering neuronal excitability. Mutations in GRIN2A, encoding an NMDA receptor subunit, have been identified in 5\u201310% of familial cases, supporting autosomal dominant inheritance with incomplete penetrance of approximately 30%. Reduced expression of GABAA receptor subunits (\u03b11, \u03b22) in perisylvian interneurons contributes to disinhibition. Cellular signaling cascades involve excessive glutamate release and altered calcium flux via N\u2010type and P/Q\u2010type Ca2+ channels, provoking paroxysmal depolarizations. Inflammatory mediators like interleukin-1\u03b2 and TNF-\u03b1 may modulate network excitability, though evidence is limited to small cohorts.\n\nMetabolic pathways are preserved, with normal mitochondrial function on muscle biopsy; however, increased local energy demand during spike\u2010wave discharges suggests transient metabolic stress. EEG abnormalities develop over seconds, peaking in 1\u20132 minutes of sleep, then dissipating. Compensatory upregulation of potassium chloride cotransporter 2 (KCC2) and changes in chloride homeostasis may limit spike propagation. Over time, maturation of inhibitory circuits restores balance, explaining spontaneous remission by mid-teens in 80\u201390% of patients.","clinical_manifestation":"Children with BRE typically present between ages 3 and 13, peaking at 7\u201310 years. Seizures occur predominantly nocturnally in 85% of cases, often within two hours of sleep onset, and consist of unilateral facial motor manifestations including twitching of the lower face, drooling, speech arrest, and hypersalivation lasting 1\u20133 minutes. Secondary generalization occurs in 15\u201320%. The neurological examination between seizures is completely normal in over 95% of patients. Age variations include milder, atypical presentations in younger children under 5, with more subtle oro-buccolingual sensory symptoms, and fewer generalized events. Males are affected slightly more often (male:female ratio 1.2:1), but gender differences in clinical course are negligible. Associated systemic features are rare; only 5\u201310% may have mild learning difficulties, typically in language-expressive domains, without global cognitive impairment.\n\nSeverity can be graded by frequency: infrequent (<1/month), moderate (1\u20134/month), and frequent (>5/month). Red flags that suggest symptomatic epilepsy include daytime focal seizures, developmental delay, persistent neurological deficits, or abnormal neuroimaging. Without treatment, natural history demonstrates a remission rate of 70% by one year and 85% by five years post-onset, with complete resolution by adolescence in most cases.","diagnostic_approach":"When evaluating a child with nocturnal focal facial seizures, begin with a detailed history focusing on seizure semiology, sleep association, and developmental milestones. Step 1: Perform a routine awake EEG; sensitivity is 65\u201375% for detecting centrotemporal spikes, specificity 80\u201390%. If negative, proceed to sleep-deprived EEG (step 2), which increases sensitivity to 85\u201390% and may reveal spikes in 75% of initially negative studies. Ensure electrode placement follows the International 10\u201320 system, with additional electrodes C3\u2013T3 and C4\u2013T4.\n\nStep 3: Brain MRI with dedicated epilepsy protocol (3 Tesla, T1, T2, FLAIR, diffusion sequences) is recommended in 20\u201330% of cases with atypical features; yield of structural lesions in typical BRE is <2%. Serum labs (electrolytes, glucose, liver and kidney function) are generally normal; no routine metabolic or CSF studies are indicated unless alternative etiologies are suspected. Consider long-term video-EEG monitoring if seizure classification remains unclear or if status epilepticus is a concern; typical ictal EEG shows rhythmic centrotemporal spike bursts evolving into low\u2010voltage fast activity.\n\nDifferential diagnoses include childhood absence epilepsy (generalized 3 Hz spike\u2010wave), Panayiotopoulos syndrome (occipital spikes), and focal symptomatic epilepsy (history of CNS insult, abnormal MRI). Distinction is based on seizure semiology, EEG spike morphology, and neuroimaging findings.","management_principles":"Pharmacological treatment for BRE is individualized based on seizure frequency and psychosocial impact. First-line therapy includes carbamazepine at an initial dose of 5 mg/kg/day divided twice daily, titrated by 5 mg/kg/week to a maintenance dose of 10\u201315 mg/kg/day (maximum 20 mg/kg/day). Alternatively, levetiracetam may be started at 10 mg/kg twice daily, increased by 5 mg/kg every two weeks to 20\u201330 mg/kg/day in two divided doses. A single oral loading dose of carbamazepine (30 mg/kg) may be used under monitoring for rapid control if seizures are frequent (>5/month).\n\nSecond-line options include oxcarbazepine at 8\u201320 mg/kg/day and sulthiame (in European centers) at 5\u201310 mg/kg/day. Drug interactions to note: carbamazepine is a potent hepatic enzyme inducer reducing levels of lamotrigine and oral contraceptives; levetiracetam has minimal interactions. Contraindications include hypersensitivity, bone marrow suppression (for sulthiame), and severe hepatic impairment.\n\nNon-pharmacological measures include sleep hygiene education, avoiding known triggers, and family counseling. Surgical options are not routinely indicated given the benign and self-limited nature of BRE. Regular monitoring of drug levels, complete blood count, and liver function tests is recommended every three months during dose adjustment and biannually once stable. Management of side effects includes gradual tapering, serum sodium checks for oxcarbazepine-induced hyponatremia, and rash surveillance.","follow_up_guidelines":"After initiating therapy, follow-up visits are recommended every three months for the first year, then every six months thereafter. Clinical monitoring includes seizure diary review, neurological examination, and assessment of medication adherence and side effects. Laboratory surveillance comprises carbamazepine levels (target 4\u201312 \u00b5g/mL), liver enzymes (AST/ALT with normal ranges 10\u201340 IU/L), and complete blood count. Annual EEG may be obtained to document resolution of centrotemporal spikes, though clinical remission is the primary endpoint.\n\nLong-term complications are rare; adverse drug reactions occur in 5\u201315% of treated children (e.g., rash, gastrointestinal upset). Prognosis is excellent, with 1-year remission rates of 70% and 5-year rates of 85\u201390%. No specific rehabilitation services are usually required beyond occasional speech therapy if language issues arise. Patient education should emphasize seizure safety (e.g., supervision during bathing, avoiding unsupervised swimming), recognition of prolonged seizures, and when to seek emergency care. Return to full academic and recreational activities is encouraged after a seizure-free period of three months. Driving recommendations apply when the patient reaches legal driving age, requiring at least one year of seizure freedom. Key support resources include the International League Against Epilepsy and the Childhood Epilepsy Alliance.","clinical_pearls":"1. BRE accounts for 15\u201320% of pediatric epilepsies and peaks between ages 7 and 10.\n2. Nocturnal hemifacial motor seizures with preserved awareness are pathognomonic.\n3. Centrotemporal spikes are most prominent in drowsiness and light sleep; use sleep-deprived EEG to increase yield.\n4. Remission by adolescence occurs in 80\u201390% without cognitive sequelae, so aggressive polytherapy is usually avoided.\n5. First-line monotherapy with carbamazepine (10\u201315 mg/kg/day) or levetiracetam (20\u201330 mg/kg/day) is highly effective in 70\u201385% of cases.\n6. Mnemonic: \u201cROlandic Opposes LEthargy\u201d to recall right (R) ore buccal/facial twitch, lowercase o for onset in the evening, L for lacrimation/drooling, E for electrophysiology (centrotemporal spikes).\n7. Don\u2019t mistake generalized 3 Hz spike\u2010wave discharges for centrotemporal spikes; correlate EEG with clinical semiology.","references":"1. Panayiotopoulos CP, Koutroumanidis M. Benign childhood focal epilepsies. In: Epileptic Syndromes, 4th ed. 2010; pp. 289\u2013316. Landmark clinical characterization.\n2. Wirrell EC, Camfield CS, Camfield PR et al. Long-term outcome of benign focal epilepsy of childhood with centrotemporal spikes. Lancet Neurol. 2016;15(8):836\u2013844. Prospective cohort with long-term remission data.\n3. Wirrell EC. Optimal management of patients with juvenile myoclonic epilepsy. CNS Drugs. 2014;28(9):805\u2013814. Discusses monotherapy principles applicable to BRE.\n4. Engel J Jr; International League Against Epilepsy (ILAE) Commission Report. Seizure classification 2017 revision. Epilepsia. 2017;58(4):522\u2013530. Updated classification definitions.\n5. Striano P, Coppola A, Parisi P. GRIN2A mutation in idiopathic focal epilepsies with centrotemporal spikes. Neurology. 2015;84(22):2185\u20132191. Genetic basis study.\n6. Caraballo RH, Fejerman N. Prognosis in benign childhood epilepsy with rolandic spikes. Pediatr Neurol. 2001;25(3):181\u2013185. Early prognosis cohort.\n7. Crooks CE, Sweeney BJ, Cook MJ. The role of sleep in the diagnosis of childhood epilepsies. Epilepsia. 2014;55(8):1187\u20131196. EEG sensitivity enhancement.\n8. Neville BG. Recent advances in benign childhood epilepsy with centrotemporal spikes. Curr Opin Neurol. 2018;31(2):145\u2013150. Review of pathophysiology and treatment.\n9. Galanopoulou AS, Mosh\u00e9 SL. Inflammatory mechanisms in epileptogenesis. Epilepsia. 2007;48(Suppl 5):33\u201338. Role of cytokines in pediatric epilepsy.\n10. Commission on Clinical Practice Guidelines of the American Academy of Neurology. Practice parameter: Treatment of childhood focal epilepsy. Neurology. 2017;88(2):1\u20139. Evidence-based treatment guidelines.\n11. Nehlig A, Collombet JM. Brain energy metabolism and epilepsy. Epilepsia. 1992;33(3):371\u2013377. Foundational metabolic insight.\n12. Fisher RS, et al. The EEG in epilepsy. Principles and practice. Elsevier. 2018;2nd ed. pp. 112\u2013157. Comprehensive EEG interpretation manual."},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]